Acquiring Company
Eli Lilly and Company
Acquired Company
POINT Biopharma
Indianapolis
TorontoManufacturingBiotechnologyHealth CareMedicalPharmaceuticalBiotechnologyDescription
Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of POINT Biopharma Global Inc. (NASDAQ: PNT), a radiopharmaceutical company with a pipeline of clinical and preclinical-stage radioligand therapies in development for the treatment of cancer.
Quick answer
Eli Lilly and Company is acquiring POINT Biopharma, announced December 27, 2023. Eli Lilly and Company is based in Indianapolis, Indiana, United States.
- How much did Eli Lilly and Company pay for POINT Biopharma?
- The deal value was not disclosed.
- What does Eli Lilly and Company do?
- Lilly is a medicine company turning science into healing to make life better for people around the world.
- Where are Eli Lilly and Company and POINT Biopharma based?
- Eli Lilly and Company is based in Indianapolis, Indiana, United States. POINT Biopharma is based in Toronto, Ontario, Canada.
- Who are the decision-makers at Eli Lilly and Company?
- Fundz holds 5 contacts at Eli Lilly and Company. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Medical and Pharmaceutical
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Bristol Myers Squibb Completes Acquisition of Mirati Therapeutics, Strengthening and Diversifying Oncology Portfolio (January 23, 2024)
- Novo Holdings to Acquire Catalent (February 5, 2024)
- Myriad Genetics to Acquire Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics (January 18, 2024)
- Abbvie To Acquire Immunogen, Including Its Flagship Cancer Therapy Elahere® (Mirvetuximab Soravtansine-Gynx), Expanding Solid Tumor Portfolio (November 30, 2023)
- Aurora Cannabis Acquires MedReleaf Australia (February 8, 2024)
- Immunome to Acquire AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals (February 6, 2024)
Who to call at Eli Lilly and Company, and when
When Eli Lilly and Company changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Eli Lilly and Company raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Eli Lilly and Company, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Eli Lilly and Company. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Eli Lilly and Company makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired POINT Biopharma?
POINT Biopharma was acquired by Eli Lilly and Company, based in Indianapolis. The deal was reported on December 27, 2023. Lilly is a medicine company turning science into healing to make life better for people around the world. Eli Lilly and Company is publicly traded (LLY) and operates in Manufacturing.
When did Eli Lilly and Company acquire POINT Biopharma?
Eli Lilly and Company's acquisition of POINT Biopharma was reported on December 27, 2023. Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of POINT Biopharma Global Inc. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does POINT Biopharma do?
POINT Biopharma develops next-generation radioligand therapies for the treatment of cancer It is privately held, operating in Biotechnology, and is based in Toronto.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.